RESUMEN

The rapid and widespread increase in pharmaceutical micropollutants (PMPs) poses a significant and immediate threat to ecosystems and human health globally. With the demand for clean water becoming increasingly critical, particularly amid escalating global water scarcity challenges, there is an urgent need for innovative approaches. Among the potential solutions, metal oxide photocatalysts such as titanium dioxide-based (TiB) and zinc oxide-based (ZnB) have garnered attention due to their cost-effectiveness, efficient photodegradation capabilities, and inherent stability. This comprehensive review explores recent advancements in the application of TiB and ZnB for the removal of PMPs from wastewater. It examines the multifaceted impacts of PMPs on environmental and public health, evaluates various techniques for their removal, and assesses design strategies aimed at maximizing the photocatalytic efficiency of TiB and ZnB. The mechanisms responsible for the photocatalytic degradation of pharmaceutical micropollutants using TiB and ZnB photocatalysts are comprehensively detailed. Finally, the review outlines the prospects and challenges associated with the use of TiB and ZnB photocatalysts for the removal of PMPs from wastewater. It emphasizes their potential to effectively mitigate PMP contaminants and make substantial contributions to sustainable water management practices in the face of escalating environmental and public health concerns.

Asunto(s)

RESUMEN

Recently, the hazardous effects of antibiotic micropollutants on the environment and human health have become a major concern. To address this challenge, semiconductor-based photocatalysis has emerged as a promising solution for environmental remediation. Our study has developed Bi2WO6/g-C3N4 (BWCN) photocatalyst with unique characteristics such as reactive surface sites, enhanced charge transfer efficiency, and accelerated separation of photogenerated electron-hole pairs. BWCN was utilized for the oxidation of tetracycline antibiotic (TCA) in different water sources. It displayed remarkable TCA removal efficiencies in the following order: surface water (99.8%) > sewage water (88.2%) > hospital water (80.7%). Further, reusability tests demonstrated sustained performance of BWCN after three cycles with removal efficiencies of 87.3, 71.2 and 65.9% in surface water, sewage, and hospital water, respectively. A proposed photocatalytic mechanism was delineated, focusing on the interaction between reactive radicals and TCA molecules. Besides, the transformation products generated during the photodegradation of TCA were determined, along with the discussion on the potential risk assessment of antibiotic pollutants. This study introduces an approach for utilizing BWCN photocatalyst, with promising applications in the treatment of TCA from various wastewater sources.

Asunto(s)

RESUMEN

Ciprofloxacin antibiotic (CIP) is one of the antibiotics with the highest rate of antibiotic resistance, if used and managed improperly, can have a negative impact on the ecosystem. In this research, ZnO modified g-C3N4 photocatalyst was prepared and applied for the decomposition of CIP antibiotic compounds in water. The removal performance of CIP by using ZnO/g-C3N4 reached 93.8% under pH 8.0 and an increasing amount of catalyst could improve the degradation performance of the pollutant. The modified ZnO/g-C3N4 completely oxidized CIP at a low concentration of 1 mg L-1 and the CIP removal efficiency slightly decreases (around 13%) at a high level of pollutant (20 mg L-1). The degradation rate of CIP by doped sample ZnO/g-C3N4 was 4.9 times faster than that of undoped g-C3N4. The doped catalyst ZnO/g-C3N4 also displayed high reusability for decomposition of CIP with 89.8% efficiency remaining after 3 cycles. The radical species including ·OH, ·O2- and h+ are important in the CIP degradation process. In addition, the proposed mechanism for CIP degradation by visible light-assisted ZnO/g-C3N4 was claimed.

Asunto(s)

RESUMEN

WHAT IS KNOWN AND OBJECTIVE: Use of cisplatin can induce type I hypersensitivity reactions that may also be linked to the quality of the drug utilized. We observed cases of hypersensitivity that appeared to be associated with the brand of cisplatin used. The aim of this study was to compare two different brands of cisplatin in relation to type I hypersensitivity reactions. METHODS: Brand A was used in a tertiary care teaching hospital until 2012, and use of brand B started from January 2013, when the first hypersensitivity cases were observed. Patients were categorized based on symptom. Cisplatin of both brands was analysed by high-performance liquid chromatography (HPLC) and high-resolution electrospray ionization mass spectrometry (ESI-(+)-MS) and characterized according to US Pharmacopeia. RESULTS AND DISCUSSION: There were no cases of hypersensitivity associated with the use of cisplatin brand A, whereas four of 127 outpatients that used cisplatin brand B were affected. The two brands were in accordance with the US Pharmacopeia parameters, and there was no significant difference in the total platinum levels between the two brands when analysed by HPLC. However, high-resolution ESI-(+)-MS analyses show that brand B contains approximately 2.7 times more hydrolysed cisplatin than brand A. WHAT IS NEW AND CONCLUSION: The increase in the hydrolysed form of cisplatin found in brand B may be the cause of the hypersensitivity reaction observed in a subset of patients. We present the first study of the quality of drugs by high-resolution ESI-(+)-MS. Drug regulatory agencies and manufacturers should consider including measurement of hydrolysed cisplatin as a quality criterion for cisplatin formulations.

Asunto(s)

RESUMEN

The activation of gelsolin by calcium has been postulated to be involved in the receptor-mediated reorganization of the actin cytoskeleton, but cytoskeletal reorganization can also occur in cells with intracellular Ca2+ clamped at nanomolar levels. Fluorescence measurements using Fura-2 show that at pH 7.4, the Ca2+ requirement for gelsolin activation in vitro is higher than previously reported, with half-maximal activation of severing and nucleation occurring at 10 microM Ca2+. The Ca2+ requirement for gelsolin activity decreases at more acid pH and is approximately 3 microM at pH 6.5. At pH below 6.0, gelsolin no longer requires Ca2+ for activity and severs actin filaments, binds two actin monomers, and nucleates filament formation in EGTA-containing solutions. The pH-activated severing activity is inhibited by mixed lipid vesicles containing phosphatidylinositol 4,5-bisphosphate. A Ca(2+)-sensitive fragment consisting of the first 135 amino acids of human cytoplasmic gelsolin also demonstrates severing activity at pH < 6.0 in the absence of Ca2+. In contrast, the gelsolin homologs severin and villin maintain Ca2+ regulation of severing activity at low pH. These differences suggest that activation of gelsolin at low pH cannot be explained merely by destabilization of F-actin. The difference in diffusion constants of gelsolin measured at pH 5.5 and 6.5, as determined by dynamic light scattering, suggests that the molecule undergoes a shape change similar to that reported upon binding Ca2+ at neutral pH. These results suggest a mechanism by which gelsolin may be activated in vivo under conditions where Ca2+ transients do not occur.

Asunto(s)

RESUMEN

An underlying cause of type III hyperlipoproteinemia is the presence of variant forms of apolipoprotein (apo) E that are defective in binding to apo B,E low density lipoprotein receptors. This disorder is associated almost exclusively with the apo E2/2 phenotype. However, structural and functional heterogeneity have been demonstrated within this phenotype. The apo E2(Arg158----Cys) variant, displaying 1% of normal apo E3 binding activity, is the most defective known form. In this study, we describe a method in which a pair of 19-mer synthetic oligonucleotide probes were used to distinguish between DNA coding for arginine or cysteine at position 158 in apo E. The specificity of the probes was demonstrated by using DNA from subjects whose apo E protein sequence or phenotype was known. The probes were used to screen a French-Canadian population of 34 apo E2/2 subjects to determine the frequency of the apo E2(Arg158----Cys) variant. All 34 subjects, most of whom displayed clinical or biochemical features of type III hyperlipoproteinemia, were found to be homozygous for apo E2(Arg158----Cys), strongly suggesting that this variant is the most common form of apo E2 within this ethnic and clinical population. In addition, the utility of this approach in detecting new apo E mutants was demonstrated when DNA from one of the apo E3/3 control subjects, whose family has a history of hyperlipidemia and coronary artery disease, reacted with both probes. This result suggests that this subject is heterozygous for normal apo E3 and a new apo E3 variant that is likely to be functionally equivalent to apo E2(Arg158----Cys).

Asunto(s)

Asunto(s)